{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T06:01:44Z","timestamp":1785132104112,"version":"3.55.0"},"reference-count":162,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurosci."],"abstract":"<jats:p>\n                    Progressive Supranuclear Palsy (PSP) is the most prevalent primary 4R-tauopathy, characterized by the pathogenic accumulation of misfolded tau protein within neurons and glial cells. Historically, clinical diagnosis relied upon the identification of Richardson\u2019s Syndrome, however, the recognition of diverse clinical phenotypes that overlap with Parkinson\u2019s disease, corticobasal syndrome, and frontotemporal dementia has complicated the diagnostic landscape and hindered the success of developing therapeutic interventions. As the field transitions toward a precision medicine paradigm, there is a growing need for validated biomarkers that can provide molecular specificity, facilitate early diagnosis, and accurately track disease progression. This paper reviews the recent advancements in neuroimaging and fluid-based biomarkers, assessing their potential to delineate PSP from similar neurodegenerative conditions and unlock the 4R-tau therapeutic pipeline. In the domain of neuroimaging, while structural magnetic resonance imaging (MRI) and the Magnetic Resonance Parkinsonism Index (MRPI) continue to provide measures of subcortical atrophy, the emergence of second-generation tau-selective positron emission tomography (PET) radioligands represents a transformative shift. New tau PET tracers offer the ability to visualize tau pathology\n                    <jats:italic>in vivo<\/jats:italic>\n                    , providing a more direct assessment of the underlying proteinopathy than traditional volumetric measures. These advancements are complemented by significant progress in fluid biomarkers. Plasma phosphorylated tau at residue 217 (p-tau217) has gained prominence as a robust marker for Alzheimer\u2019s disease, and its primary utility in PSP research currently serves as a critical negative signature to exclude amyloid-associated co-pathology. In contrast, novel assays targeting microtubule-binding region tau fragments show burgeoning potential for the specific identification of 4R-tau isoforms. Furthermore, neurofilament light chain (NfL) has been firmly established as a sensitive, albeit non-specific, indicator of neuroaxonal injury and clinical severity. Additional advancements with digital health approaches and electrophysiological assessments add to the opportunities for improved objective measures. This review concludes that the shift from clinical-only diagnostic criteria to a biomarker-enabled molecular framework is the necessary catalyst for developing effective disease-modifying therapies for PSP and related 4R-tauopathies. The synthesis of these multimodal biomarkers into a unified framework will be essential to improve participant stratification, enable the use of adaptive trial models, and provide supportive evidence of target engagement for future clinical trials.\n                  <\/jats:p>","DOI":"10.3389\/fnins.2026.1893149","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T05:40:39Z","timestamp":1785130839000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["From clinical phenotypes to molecular precision: multimodal biomarkers for progressive supranuclear palsy"],"prefix":"10.3389","volume":"20","author":[{"given":"Glenn A.","family":"Harris","sequence":"first","affiliation":[{"name":"Rainwater Charitable Foundation","place":["Fort Worth, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lymor","family":"Barnhard","sequence":"additional","affiliation":[{"name":"Rainwater Charitable Foundation","place":["Fort Worth, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Brummet","sequence":"additional","affiliation":[{"name":"CurePSP Inc.","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristophe","family":"Diaz","sequence":"additional","affiliation":[{"name":"CurePSP Inc.","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"105345","DOI":"10.1016\/j.parkreldis.2023.105345","article-title":"Wearable sensors for assessing disease severity and progression in progressive Supranuclear palsy","volume":"109","author":"Abate","year":"2023","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/braincomms\/fcae233","article-title":"Patterns of brain volume and metabolism predict clinical features in the progressive supranuclear palsy spectrum","volume":"6","author":"Ali","year":"2024","journal-title":"Brain Commun."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"9297","DOI":"10.1038\/s41598-021-88877-2","article-title":"Gait analysis may distinguish progressive supranuclear palsy and Parkinson disease since the earliest stages","volume":"11","author":"Amboni","year":"2021","journal-title":"Sci. Rep."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.3390\/biomedicines13051009","article-title":"Can progressive Supranuclear palsy be accurately identified via MRI with the use of visual rating scales and signs?","volume":"13","author":"Anyfantakis","year":"2025","journal-title":"Biomedicine"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1002\/alz.12841","article-title":"Plasma and CSF biomarkers in a memory clinic: head-to-head comparison of phosphorylated tau immunoassays","volume":"19","author":"Ashton","year":"2023","journal-title":"Alzheimers Dement."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.3390\/brainsci12091126","article-title":"Epidemiology of progressive Supranuclear palsy: Real world data from the second largest health Plan in Israel","volume":"12","author":"Barer","year":"2022","journal-title":"Brain Sci."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"302","DOI":"10.3389\/fnagi.2025.1569302","article-title":"Diffusion tensor imaging of sequential neuropathological patterns in progressive supranuclear palsy","volume":"17","author":"B\u00e2rlescu","year":"2025","journal-title":"Front. Aging Neurosci."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3389\/fnagi.2024.1380561","article-title":"SV2A PET imaging in human neurodegenerative diseases","volume":"16","author":"Bavarsad","year":"2024","journal-title":"Front. Aging Neurosci."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3233\/JAD-215616","article-title":"Neurofilament light chain levels in frontotemporal dementia and progressive Supranuclear palsy: a systematic review","volume":"87","author":"Bendstrup","year":"2022","journal-title":"J. Alzheimer's Dis"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"14482","DOI":"10.1002\/alz.14482","article-title":"Plasma p-tau217 and neurofilament\/p-tau217 ratio in differentiating Alzheimer\u2019s disease from syndromes associated with frontotemporal lobar degeneration","volume":"21","author":"Benussi","year":"2025","journal-title":"Alzheimers Dement."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"483","DOI":"10.3389\/fneur.2018.00483","article-title":"Clinical routine FDG-PET imaging of suspected progressive Supranuclear palsy and Corticobasal degeneration: a gatekeeper for subsequent tau-PET imaging?","volume":"9","author":"Beyer","year":"2018","journal-title":"Front. Neurol."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/S1474-4422(14)70088-2","article-title":"Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2\/3 trial","volume":"13","author":"Boxer","year":"2014","journal-title":"Lancet Neurol."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/S1474-4422(17)30157-6","article-title":"Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches","volume":"16","author":"Boxer","year":"2017","journal-title":"Lancet Neurol."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1080\/01616412.2017.1312211","article-title":"The utility of FDG-PET in the differential diagnosis of parkinsonism","volume":"39","author":"Brajkovic","year":"2017","journal-title":"Neurol. Res."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1001\/jamaneurol.2020.2526","article-title":"Assessment of 18 F-PI-2620 as a biomarker in progressive Supranuclear palsy","volume":"77","author":"Brendel","year":"2020","journal-title":"JAMA Neurol."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1136\/jnnp-2024-333590","article-title":"Added value of FDG-PET for detection of progressive supranuclear palsy","volume":"96","author":"Buchert","year":"2025","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s00401-025-02951-x","article-title":"LRRK2 kinase-mediated accumulation of lysosome-associated phospho-Rabs in tauopathies and synucleinopathies","volume":"150","author":"Buck","year":"2025","journal-title":"Acta Neuropathol."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1093\/braincomms\/fcad305","article-title":"A review of the flortaucipir literature for positron emission tomography imaging of tau neurofibrillary tangles","volume":"6","author":"Burnham","year":"2023","journal-title":"Brain Commun."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"123617","DOI":"10.1016\/j.jns.2025.123617","article-title":"The role of blood-based biomarkers in parkinsonian disorders, Alzheimer\u2019s disease and frontotemporal dementia","volume":"476","author":"Campagnolo","year":"2025","journal-title":"J. Neurol. Sci."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s40478-020-00990-x","article-title":"Towards an improved early diagnosis of neurodegenerative diseases: the emerging role of in vitro conversion assays for protein amyloids","volume":"8","author":"Candelise","year":"2020","journal-title":"Acta Neuropathol. Commun."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"60S","DOI":"10.2967\/jnumed.121.263201","article-title":"Imaging of synaptic density in neurodegenerative disorders","volume":"63","author":"Carson","year":"2022","journal-title":"J. Nucl. Med."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"5108","DOI":"10.1073\/pnas.1807983116","article-title":"Neuromelanin-sensitive MRI as a noninvasive proxy measure of dopamine function in the human brain","volume":"116","author":"Cassidy","year":"2019","journal-title":"Proc. Natl. Acad. Sci."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1097\/WCO.0000000000001035","article-title":"Overview of tau PET molecular imaging","volume":"35","author":"Cassinelli Petersen","year":"2022","journal-title":"Curr. Opin. Neurol."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"119975","DOI":"10.1016\/j.cca.2024.119975","article-title":"Diagnostic value of six plasma biomarkers in progressive supranuclear palsy, multiple system atrophy, and Parkinson\u2019s disease","volume":"565","author":"Chen","year":"2025","journal-title":"Clin. Chim. Acta"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"111476","DOI":"10.1016\/j.brainresbull.2025.111476","article-title":"Machine learning approach effectively discriminates between Parkinson\u2019s disease and progressive supranuclear palsy: multi-level indices of rs-fMRI","volume":"229","author":"Cheng","year":"2025","journal-title":"Brain Res. Bull."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13195-020-00588-4","article-title":"The clinical promise of biomarkers of synapse damage or loss in Alzheimer\u2019s disease","volume":"12","author":"Colom-Cadena","year":"2020","journal-title":"Alzheimers Res. Ther."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/ane.13116","article-title":"Cerebrospinal fluid neurofilament light and tau protein as mortality biomarkers in Parkinsonism","volume":"140","author":"Constantinescu","year":"2019","journal-title":"Acta Neurol. Scand."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1093\/brain\/awx347","article-title":"Tau burden and the functional connectome in Alzheimer\u2019s disease and progressive supranuclear palsy","volume":"141","author":"Cope","year":"2018","journal-title":"Brain"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"11624","DOI":"10.3390\/ijms241411624","article-title":"Neurofilament-light, a promising biomarker: analytical, metrological and clinical challenges","volume":"24","author":"Coppens","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"ref30","doi-asserted-by":"publisher","first-page":"629","DOI":"10.3389\/fnagi.2022.872629","article-title":"The future of seed amplification assays and clinical trials","volume":"14","author":"Coysh","year":"2022","journal-title":"Front. Aging Neurosci."},{"key":"ref31","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1007\/s00259-025-07579-3","article-title":"Comparing and combining TSPO-PET tracers in tauopathies","volume":"53","author":"Crook","year":"2026","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"5442","DOI":"10.1038\/s41467-024-55442-0","article-title":"A 15-item modification of the PSP rating scale to improve clinical meaningfulness and statistical performance","volume":"16","author":"Dam","year":"2025","journal-title":"Nat. Commun."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.bbi.2023.07.023","article-title":"TSPO PET brain inflammation imaging: a transdiagnostic systematic review and meta-analysis of 156 case-control studies","volume":"113","author":"De Picker","year":"2023","journal-title":"Brain Behav. Immun."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"9161","DOI":"10.1038\/s41598-020-66090-x","article-title":"Differential levels of Neurofilament light protein in cerebrospinal fluid in patients with a wide range of neurodegenerative disorders","volume":"10","author":"Delaby","year":"2020","journal-title":"Sci. Rep."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s10072-024-07833-w","article-title":"Speech profile in different clinical PSP phenotypes: an acoustic-perceptual study","volume":"46","author":"Di Rauso","year":"2025","journal-title":"Neurol. Sci."},{"key":"ref36","doi-asserted-by":"publisher","first-page":"305","DOI":"10.3390\/pathogens10030305","article-title":"The latest research on RT-QuIC assays\u2014a literature review","volume":"10","author":"Dong","year":"2021","journal-title":"Pathogens"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.parkreldis.2018.06.018","article-title":"Serum neurofilament light chain in progressive supranuclear palsy","volume":"56","author":"Donker Kaat","year":"2018","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref38","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.neulet.2011.01.020","article-title":"Disease specificity and pathologic progression of tau pathology in brainstem nuclei of Alzheimer\u2019s disease and progressive supranuclear palsy","volume":"491","author":"Dugger","year":"2011","journal-title":"Neurosci. Lett."},{"key":"ref39","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/alz.70116","article-title":"Novel blood-based proteomic signatures across multiple neurodegenerative diseases","volume":"21","author":"Durcan","year":"2025","journal-title":"Alzheimers Dement."},{"key":"ref40","doi-asserted-by":"publisher","first-page":"7880","DOI":"10.1038\/s41467-024-52025-x","article-title":"Genetic, transcriptomic, histological, and biochemical analysis of progressive supranuclear palsy implicates glial activation and novel risk genes","volume":"15","author":"Farrell","year":"2024","journal-title":"Nat. Commun."},{"key":"ref41","doi-asserted-by":"publisher","first-page":"8129","DOI":"10.1002\/alz.14250","article-title":"A framework for translating tauopathy therapeutics: drug discovery to clinical trials","volume":"20","author":"Feldman","year":"2024","journal-title":"Alzheimers Dement."},{"key":"ref42","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nature23002","article-title":"Cryo-EM structures of tau filaments from Alzheimer\u2019s disease","volume":"547","author":"Fitzpatrick","year":"2017","journal-title":"Nature"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.tins.2023.07.006","article-title":"Alzheimer\u2019s disease and related tauopathies: disorders of disrupted neuronal identity","volume":"46","author":"Frost","year":"2023","journal-title":"Trends Neurosci."},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1136\/jnnp.2003.027367","article-title":"Abnormalities of optokinetic nystagmus in progressive supranuclear palsy","volume":"75","author":"Garbutt","year":"2004","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/ene.70068","article-title":"Tau PET imaging with [18F] MK-6240: limited affinity for primary Tauopathies and high specificity for Alzheimer\u2019s disease","volume":"32","author":"G\u00e9rard","year":"2025","journal-title":"Eur. J. Neurol."},{"key":"ref46","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/mds.20668","article-title":"In vivo imaging of microglial activation with [11C](R)-PK11195 PET in progressive supranuclear palsy","volume":"21","author":"Gerhard","year":"2006","journal-title":"Mov. Disord."},{"key":"ref47","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1002\/mds.30001","article-title":"Quantitative comparisons of progressive Supranuclear palsy rating scale versions using item response theory","volume":"39","author":"Gewily","year":"2024","journal-title":"Mov. Disord."},{"key":"ref48","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s00401-025-02864-9","article-title":"High resolution autoradiography of [18F]MK-6240 and [18F]Flortaucipir shows similar neurofibrillary tangle binding patterns preferentially recognizing middling neurofibrillary tangle maturity","volume":"149","author":"Ghatamaneni","year":"2025","journal-title":"Acta Neuropathol."},{"key":"ref49","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s00415-026-13666-8","article-title":"Eye tracking as a digital biomarker in neurodegenerative diseases","volume":"273","author":"Giacomini","year":"2026","journal-title":"J. Neurol."},{"key":"ref50","doi-asserted-by":"publisher","first-page":"8278","DOI":"10.3390\/ijms26178278","article-title":"A review of FDG-PET in progressive Supranuclear palsy and Corticobasal syndrome","volume":"26","author":"Giannakis","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"ref51","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1093\/brain\/awm032","article-title":"A clinical rating scale for progressive supranuclear palsy","volume":"130","author":"Golbe","year":"2007","journal-title":"Brain"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1038\/s41467-024-47286-5","article-title":"Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer\u2019s disease","volume":"15","author":"Gonzalez-Ortiz","year":"2024","journal-title":"Nat. Commun."},{"key":"ref53","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1093\/brain\/awac407","article-title":"Brain-derived tau: a novel blood-based biomarker for Alzheimer\u2019s disease-type neurodegeneration","volume":"146","author":"Gonzalez-Ortiz","year":"2023","journal-title":"Brain"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1002\/mds.28470","article-title":"A modified progressive Supranuclear palsy rating scale","volume":"36","author":"Gr\u00f6tsch","year":"2021","journal-title":"Mov. Disord."},{"key":"ref55","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/acn3.378","article-title":"Extended and direct evaluation of RT-QuIC assays for Creutzfeldt-Jakob disease diagnosis","volume":"4","author":"Groveman","year":"2017","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref56","doi-asserted-by":"publisher","first-page":"4920","DOI":"10.1007\/s00415-022-11136-5","article-title":"Eye tracking identifies biomarkers in \u03b1-synucleinopathies versus progressive supranuclear palsy","volume":"269","author":"Habibi","year":"2022","journal-title":"J. Neurol."},{"key":"ref57","author":"Hahn","year":"2024"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13195-025-01775-x","article-title":"Revisiting the therapeutic landscape of tauopathies: assessing the current pipeline and clinical trials","volume":"17","author":"Harris","year":"2025","journal-title":"Alzheimer's Res. Ther."},{"key":"ref59","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/S1474-4422(20)30489-0","article-title":"Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial","volume":"20","author":"H\u00f6glinger","year":"2021","journal-title":"Lancet Neurol."},{"key":"ref60","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/mds.26987","article-title":"Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria","volume":"32","author":"H\u00f6glinger","year":"2017","journal-title":"Mov. Disord."},{"key":"ref61","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1002\/mds.28188","article-title":"Synaptic loss in primary Tauopathies revealed by [11C] UCB-J positron emission tomography","volume":"35","author":"Holland","year":"2020","journal-title":"Mov. Disord."},{"key":"ref62","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1093\/brain\/awab282","article-title":"Molecular pathology and synaptic loss in primary tauopathies: an 18F-AV-1451 and 11C-UCB-J PET study","volume":"145","author":"Holland","year":"2022","journal-title":"Brain"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1038\/s41591-022-02075-9","article-title":"CSF tau microtubule-binding region identifies pathological changes in primary tauopathies","volume":"28","author":"Horie","year":"2022","journal-title":"Nat. Med."},{"key":"ref64","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1002\/alz70861_108254","article-title":"MTBR-tau243 biomarker specifically identifies mixed 3R\/4R tauopathies","volume":"21","author":"Horie","year":"","journal-title":"Alzheimers Dement."},{"key":"ref65","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1038\/s41591-023-02443-z","article-title":"CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer\u2019s disease","volume":"29","author":"Horie","year":"2023","journal-title":"Nat. Med."},{"key":"ref66","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1038\/s41591-025-03617-7","article-title":"Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer\u2019s disease","volume":"31","author":"Horie","year":"","journal-title":"Nat. Med."},{"key":"ref67","doi-asserted-by":"publisher","first-page":"859","DOI":"10.3390\/brainsci14090859","article-title":"Alzheimer\u2019s disease-related cerebrospinal fluid biomarkers in progressive Supranuclear palsy","volume":"14","author":"Ishiguro","year":"2024","journal-title":"Brain Sci."},{"key":"ref68","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1093\/jnen\/60.6.647","article-title":"Microglial activation parallels system degeneration in progressive Supranuclear palsy and Corticobasal degeneration","volume":"60","author":"Ishizawa","year":"2001","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref69","doi-asserted-by":"publisher","first-page":"587","DOI":"10.3390\/brainsci15060587","article-title":"Pathway to regulatory approval of digital health Technologies in Progressive Supranuclear Palsy: a scoping review","volume":"15","author":"Isroff","year":"2025","journal-title":"Brain Sci."},{"key":"ref70","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement."},{"key":"ref71","doi-asserted-by":"publisher","first-page":"100389","DOI":"10.1016\/j.prdoa.2025.100389","article-title":"Digital speech assessments and machine learning for differentiation of neurodegenerative diseases","volume":"13","author":"Kang","year":"2025","journal-title":"Clin. Park. Relat. Disord."},{"key":"ref72","doi-asserted-by":"publisher","first-page":"105835","DOI":"10.1016\/j.parkreldis.2023.105835","article-title":"Utilizing speech analysis to differentiate progressive supranuclear palsy from Parkinson\u2019s disease","volume":"115","author":"Kang","year":"2023","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref73","doi-asserted-by":"publisher","first-page":"14458","DOI":"10.1002\/alz.14458","article-title":"Diagnostic accuracy of phosphorylated tau217 in detecting Alzheimer\u2019s disease pathology among cognitively impaired and unimpaired: a systematic review and meta-analysis","volume":"21","author":"Khalafi","year":"2025","journal-title":"Alzheimers Dement."},{"key":"ref74","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1136\/jnnp-2021-328586","article-title":"Neuropathology and emerging biomarkers in corticobasal syndrome","volume":"93","author":"Koga","year":"2022","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s00401-020-02158-2","article-title":"Distribution patterns of tau pathology in progressive supranuclear palsy","volume":"140","author":"Kovacs","year":"2020","journal-title":"Acta Neuropathol."},{"key":"ref76","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3389\/fnagi.2022.804385","article-title":"Differential diagnosis of rare subtypes of progressive Supranuclear palsy and PSP-like syndromes\u2014infrequent manifestations of the Most common form of atypical Parkinsonism","volume":"14","author":"Krzosek","year":"2022","journal-title":"Front. Aging Neurosci."},{"key":"ref77","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.cell.2025.12.036","article-title":"Molecular features of human pathological tau distinguish tauopathy-associated dementias","volume":"189","author":"Kumar","year":"2026","journal-title":"Cell"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"14434","DOI":"10.1212\/WNL.0000000000214434","article-title":"Patterns of longitudinal regional brain atrophy in patients with different progressive Supranuclear palsy clinical variants","volume":"105","author":"Kumar","year":"2025","journal-title":"Neurology"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"e0162460","DOI":"10.1371\/journal.pone.0162460","article-title":"Quantitative susceptibility mapping in Parkinson\u2019s disease","volume":"11","author":"Langkammer","year":"2016","journal-title":"PLoS One"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s00415-025-13570-7","article-title":"Plasma NFL, GFAP, sTREM2, pTau231, and clinical severity in progressive supranuclear palsy","volume":"273","author":"Lee","year":"2026","journal-title":"J. Neurol."},{"key":"ref81","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1038\/s41380-018-0342-8","article-title":"Tau PET imaging in neurodegenerative tauopathies\u2014still a challenge","volume":"24","author":"Leuzy","year":"2019","journal-title":"Mol. Psychiatry"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"14406","DOI":"10.1212\/WNL.0000000000214406","article-title":"Plasma pTau217 and Neurofilament light chain as Differentiative markers for progressive Supranuclear palsy from Parkinson disease","volume":"106","author":"Li","year":"2026","journal-title":"Neurology"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1002\/mds.28672","article-title":"Clinical utility of 18F-APN-1607 tau PET imaging in patients with progressive Supranuclear palsy","volume":"36","author":"Li","year":"2021","journal-title":"Mov. Disord."},{"key":"ref84","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1021\/acschemneuro.0c00801","article-title":"Radiosynthesis, in vitro and in vivo evaluation of [18F]CBD-2115 as a first-in-class radiotracer for imaging 4R-Tauopathies","volume":"12","author":"Lindberg","year":"2021","journal-title":"ACS Chem. Neurosci."},{"key":"ref85","doi-asserted-by":"publisher","first-page":"5109","DOI":"10.1038\/s41467-024-49258-1","article-title":"Ligand-based design of [18F]OXD-2314 for PET imaging in non-Alzheimer\u2019s disease tauopathies","volume":"15","author":"Lindberg","year":"2024","journal-title":"Nat. Commun."},{"key":"ref86","doi-asserted-by":"publisher","first-page":"204","DOI":"10.14336\/AD.2022.0514","article-title":"QEEG signatures are associated with nonmotor dysfunctions in Parkinson\u2019s disease and atypical parkinsonism: an integrative analysis","volume":"14","author":"Liu","year":"2023","journal-title":"Aging Dis."},{"key":"ref87","doi-asserted-by":"publisher","first-page":"4451","DOI":"10.1007\/s00415-023-11791-2","article-title":"The prevalence and incidence of progressive supranuclear palsy and corticobasal syndrome: a systematic review and meta-analysis","volume":"270","author":"Lyons","year":"2023","journal-title":"J. Neurol."},{"key":"ref88","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1038\/s41380-022-01875-2","article-title":"Discriminative binding of tau PET tracers PI2620, MK6240 and RO948 in Alzheimer\u2019s disease, corticobasal degeneration and progressive supranuclear palsy brains","volume":"28","author":"Malarte","year":"2023","journal-title":"Mol. Psychiatry"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1002\/ana.26543","article-title":"Synaptic loss in frontotemporal dementia revealed by [11C] UCB-J positron emission tomography","volume":"93","author":"Malpetti","year":"2023","journal-title":"Ann. Neurol."},{"key":"ref90","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.2967\/jnumed.121.262985","article-title":"In vivo 18F-Flortaucipir PET does not accurately support the staging of progressive Supranuclear palsy","volume":"63","author":"Malpetti","year":"2022","journal-title":"J. Nucl. Med."},{"key":"ref91","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1136\/jnnp-2020-325549","article-title":"Neuroinflammation predicts disease progression in progressive supranuclear palsy","volume":"92","author":"Malpetti","year":"2021","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1093\/brain\/awae269","article-title":"Blood inflammation relates to neuroinflammation and survival in frontotemporal lobar degeneration","volume":"148","author":"Malpetti","year":"2025","journal-title":"Brain"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.parkreldis.2020.05.033","article-title":"Novel decision algorithm to discriminate parkinsonism with combined blood and imaging biomarkers","volume":"77","author":"Mangesius","year":"2020","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref94","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/dad2.70123","article-title":"Brain-derived tau to measure treatment effect in Alzheimer\u2019s disease and frontotemporal dementia","volume":"17","author":"Marotta","year":"2025","journal-title":"Alzheimers Dement"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1093\/braincomms\/fcaf022","article-title":"Biomarkers of disease progression in progressive supranuclear palsy for use in clinical trials","volume":"7","author":"Marotta","year":"2024","journal-title":"Brain Commun."},{"key":"ref96","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1212\/WNL.0000000000007179","article-title":"Serum NFL discriminates Parkinson disease from atypical parkinsonisms","volume":"92","author":"Marques","year":"2019","journal-title":"Neurology"},{"key":"ref97","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1038\/s41591-026-04398-3","article-title":"A multimodal biomarker strategy to enhance diagnostic precision in neurodegenerative Parkinsonism","volume":"32","author":"Martinez-Valbuena","year":"2026","journal-title":"Nat. Med."},{"key":"ref98","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1038\/s41467-025-67744-y","article-title":"4R-tau seeding activity reveals molecular subtypes in progressive supranuclear palsy","volume":"17","author":"Martinez-Valbuena","year":"2025","journal-title":"Nat. Commun."},{"key":"ref99","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.neuron.2013.07.037","article-title":"Imaging of tau pathology in a Tauopathy mouse model and in Alzheimer patients compared to Normal controls","volume":"79","author":"Maruyama","year":"2013","journal-title":"Neuron"},{"key":"ref100","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3389\/fnbeh.2012.00088","article-title":"Validation of mobile eye-tracking as novel and efficient means for differentiating progressive supranuclear palsy from Parkinson\u2019s disease","volume":"6","author":"Marx","year":"2012","journal-title":"Front. Behav. Neurosci."},{"key":"ref101","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1002\/mds.30300","article-title":"Deep learning to differentiate parkinsonian syndromes using multimodal magnetic resonance imaging: a proof-of-concept study","volume":"40","author":"Mattia","year":"2025","journal-title":"Mov. Disord."},{"key":"ref102","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1212\/WNL.0000000000200040","article-title":"Cerebrospinal fluid biomarkers in autopsy-confirmed Alzheimer disease and frontotemporal lobar degeneration","volume":"98","author":"Mattsson-Carlgren","year":"2022","journal-title":"Neurology"},{"key":"ref103","author":"Meglio","year":"2024"},{"key":"ref104","doi-asserted-by":"publisher","first-page":"24365","DOI":"10.1038\/s41598-024-74035-x","article-title":"Differentiating neurodegenerative diseases based on EEG complexity","volume":"14","author":"Mostile","year":"2024","journal-title":"Sci. Rep."},{"key":"ref105","doi-asserted-by":"publisher","first-page":"911","DOI":"10.2967\/jnumed.119.236224","article-title":"Tau PET imaging with 18 F-PI-2620 in patients with Alzheimer disease and healthy controls: a first-in-humans study","volume":"61","author":"Mueller","year":"2020","journal-title":"J. Nucl. Med."},{"key":"ref106","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.parkreldis.2018.04.005","article-title":"The diagnostic accuracy of the hummingbird and morning glory sign in patients with neurodegenerative parkinsonism","volume":"54","author":"Mueller","year":"2018","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref107","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s00401-025-02898-z","article-title":"Multifactorial etiology of progressive supranuclear palsy (PSP): the genetic component","volume":"149","author":"M\u00fcller","year":"2025","journal-title":"Acta Neuropathol."},{"key":"ref108","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1007\/s00259-025-07413-w","article-title":"First-in-human PET neuroimaging of [18F]OXD-2314","volume":"53","author":"Murrell","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref109","doi-asserted-by":"publisher","first-page":"703984","DOI":"10.3389\/fnagi.2021.703984","article-title":"Development of \u03b1-Synuclein Real-time quaking-induced conversion as a diagnostic method for \u03b1-Synucleinopathies","volume":"13","author":"Nakagaki","year":"2021","journal-title":"Front. Aging Neurosci."},{"key":"ref110","doi-asserted-by":"publisher","first-page":"40830","DOI":"10.1101\/2025.11.24.25340830","article-title":"Biomarkers of LRRK2 and Lysosomal Dysfunction in Progressive Supranuclear Palsy","volume":"1","author":"Nielsen","year":"2025","journal-title":"MedRxiv"},{"key":"ref111","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1038\/s41591-025-03622-w","article-title":"Plasma phospho-tau217 for Alzheimer\u2019s disease diagnosis in primary and secondary care using a fully automated platform","volume":"31","author":"Palmqvist","year":"2025","journal-title":"Nat. Med."},{"key":"ref112","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1002\/mds.27964","article-title":"The progressive Supranuclear palsy clinical deficits scale","volume":"35","author":"Piot","year":"2020","journal-title":"Mov. Disord."},{"key":"ref113","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1093\/brain\/awab431","article-title":"Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies","volume":"145","author":"Poggiolini","year":"2022","journal-title":"Brain"},{"key":"ref114","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1002\/mds.28992","article-title":"Development and validation of automated magnetic resonance parkinsonism index 2.0 to distinguish progressive Supranuclear palsy-parkinsonism from Parkinson\u2019s disease","volume":"37","author":"Quattrone","year":"2022","journal-title":"Mov. Disord."},{"key":"ref115","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1148\/radiol.251394","article-title":"Planimetric and linear MRI markers for progressive Supranuclear palsy classification: a large multicohort international study","volume":"319","author":"Quattrone","year":"2026","journal-title":"Radiology"},{"key":"ref116","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1002\/mds.29866","article-title":"Magnetic resonance imaging measures to track atrophy progression in progressive Supranuclear palsy in clinical trials","volume":"39","author":"Quattrone","year":"2024","journal-title":"Mov. Disord."},{"key":"ref117","first-page":"553","article-title":"F-18-FDG PET in Richardson syndrome and PSP-P, two variants of supranuclear palsy","volume":"52","author":"Reimold","year":"2011","journal-title":"J. Nucl. Med."},{"key":"ref118","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s40478-024-01839-3","article-title":"MAPT haplotype-associated transcriptomic changes in progressive supranuclear palsy","volume":"12","author":"Ressler","year":"2024","journal-title":"Acta Neuropathol. Commun."},{"key":"ref119","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s00401-022-02479-4","article-title":"Rainwater charitable foundation criteria for the neuropathologic diagnosis of progressive supranuclear palsy","volume":"144","author":"Roemer","year":"2022","journal-title":"Acta Neuropathol."},{"key":"ref120","doi-asserted-by":"publisher","first-page":"4859","DOI":"10.1212\/WNL.0000000000004859","article-title":"CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP","volume":"90","author":"Rojas","year":"2018","journal-title":"Neurology"},{"key":"ref121","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/acn3.290","article-title":"Plasma neurofilament light chain predicts progression in progressive supranuclear palsy","volume":"3","author":"Rojas","year":"2016","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref122","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00401-020-02160-8","article-title":"Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies","volume":"140","author":"Rossi","year":"2020","journal-title":"Acta Neuropathol."},{"key":"ref123","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s00415-025-13539-6","article-title":"Diagnostic utility of biomarkers in progressive supranuclear palsy: toward a biotyping framework","volume":"273","author":"Ryan","year":"2026","journal-title":"J. Neurol."},{"key":"ref124","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jns.2015.03.041","article-title":"Neurofilament light chain level in cerebrospinal fluid can differentiate Parkinson\u2019s disease from atypical parkinsonism: evidence from a meta-analysis","volume":"352","author":"Sako","year":"2015","journal-title":"J. Neurol. Sci."},{"key":"ref125","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1007\/s00259-022-06065-4","article-title":"[18F]RO948 tau positron emission tomography in genetic and sporadic frontotemporal dementia syndromes","volume":"50","author":"Santillo","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref126","doi-asserted-by":"publisher","first-page":"120509","DOI":"10.1016\/j.neuroimage.2024.120509","article-title":"Direct comparison between 18F-Flortaucipir tau PET and quantitative susceptibility mapping in progressive supranuclear palsy","volume":"286","author":"Satoh","year":"2024","journal-title":"NeuroImage"},{"key":"ref127","doi-asserted-by":"publisher","first-page":"14409","DOI":"10.1002\/alz.14409","article-title":"Post mortem validation and mechanistic study of UCB-J in progressive supranuclear palsy patients\u2019 brains","volume":"21","author":"Scarpa","year":"2025","journal-title":"Alzheimers Dement."},{"key":"ref128","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/ana.25060","article-title":"18F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: a multicenter study","volume":"82","author":"Schonhaut","year":"2017","journal-title":"Ann. Neurol."},{"key":"ref129","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3390\/diagnostics13010006","article-title":"Differences in striatal metabolism in [18F]FDG PET in Parkinson\u2019s disease and atypical parkinsonism","volume":"13","author":"Seiffert","year":"2022","journal-title":"Diagnostics"},{"key":"ref130","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s00401-024-02816-9","article-title":"Comprehensive mapping of synaptic vesicle protein 2A (SV2A) in health and neurodegenerative diseases: a comparative analysis with synaptophysin and ground truth for PET-imaging interpretation","volume":"148","author":"Shanaki Bavarsad","year":"2024","journal-title":"Acta Neuropathol."},{"key":"ref131","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1093\/braincomms\/fcaf467","article-title":"Inflammation PET and plasma neurofilament light predict survival in people with progressive supranuclear palsy","volume":"7","author":"Shapiro","year":"2025","journal-title":"Brain Commun."},{"key":"ref132","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1186\/s12883-023-03466-2","article-title":"Remote at-home wearable-based gait assessments in progressive Supranuclear palsy compared to Parkinson\u2019s disease","volume":"23","author":"Sharma","year":"2023","journal-title":"BMC Neurol."},{"key":"ref133","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1515\/cclm-2025-0610","article-title":"Measuring neurofilament light in human plasma and cerebrospinal fluid: a comparison of five analytical immunoassays","volume":"64","author":"Sheth","year":"2026","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref134","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13024-025-00821-4","article-title":"Comprehensive cross-sectional and longitudinal comparisons of plasma glial fibrillary acidic protein and neurofilament light across FTD spectrum disorders","volume":"20","author":"Sheth","year":"2025","journal-title":"Mol. Neurodegener."},{"key":"ref135","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41586-021-03911-7","article-title":"Structure-based classification of tauopathies","volume":"598","author":"Shi","year":"2021","journal-title":"Nature"},{"key":"ref136","doi-asserted-by":"publisher","first-page":"85783","DOI":"10.1002\/alz.085783","article-title":"Functional connectivity patterns among clinical variants of progressive supranuclear palsy","volume":"20","author":"Sintini","year":"2024","journal-title":"Alzheimers Dement."},{"key":"ref137","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1002\/mds.29194","article-title":"Longitudinal monitoring of progressive Supranuclear palsy using body-worn movement sensors","volume":"37","author":"Sotirakis","year":"2022","journal-title":"Mov. Disord."},{"key":"ref138","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1148\/radiol.2019190406","article-title":"Diffusion tensor MRI to distinguish progressive Supranuclear palsy from \u03b1-Synucleinopathies","volume":"293","author":"Spotorno","year":"2019","journal-title":"Radiology"},{"key":"ref139","doi-asserted-by":"publisher","first-page":"e244266","DOI":"10.1001\/jamanetworkopen.2024.4266","article-title":"Reliability and validity of smartphone cognitive testing for frontotemporal lobar degeneration","volume":"7","author":"Staffaroni","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref140","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41582-021-00541-5","article-title":"Evolving concepts in progressive supranuclear palsy and other 4-repeat tauopathies","volume":"17","author":"Stamelou","year":"2021","journal-title":"Nat. Rev. Neurol."},{"key":"ref141","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1001\/archneur.1964.00460160003001","article-title":"Progressive Supranuclear palsy a heterogeneous degeneration involving the brain stem, Basal Ganglia and Cerebellum with Vertical Gaze and Pseudobulbar Palsy, Nucahal Dystonia and Dementia","volume":"1","author":"Steele","year":"1964","journal-title":"Arch Neurol"},{"key":"ref142","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.3390\/cells12242776","article-title":"New perspectives in radiological and radiopharmaceutical hybrid imaging in progressive Supranuclear palsy: a systematic review","volume":"12","author":"Strobel","year":"2023","journal-title":"Cells"},{"key":"ref143","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1002\/mdc3.13489","article-title":"Systematic review of prevalence studies of progressive Supranuclear palsy and Corticobasal syndrome","volume":"9","author":"Swallow","year":"2022","journal-title":"Mov. Disord. Clin. Pract."},{"key":"ref144","author":"Takahashi","year":"2002"},{"key":"ref145","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s41999-019-00211-2","article-title":"The combination of short-step and wide-based gait is a gait characteristic in progressive supranuclear palsy: a retrospective, cross-sectional study","volume":"10","author":"Takamatsu","year":"2019","journal-title":"Eur. Geriatr. Med."},{"key":"ref146","doi-asserted-by":"publisher","first-page":"12423","DOI":"10.1002\/dad2.12423","article-title":"Feasibility and acceptability of remote smartphone cognitive testing in frontotemporal dementia research","volume":"15","author":"Taylor","year":"2023","journal-title":"Alzheimers Dement"},{"key":"ref147","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S1474-4422(21)00214-3","article-title":"Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer\u2019s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study","volume":"20","author":"Thijssen","year":"2021","journal-title":"Lancet Neurol."},{"key":"ref148","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1001\/jamaneurol.2023.0488","article-title":"Evaluation of plasma phosphorylated Tau217 for differentiation between Alzheimer disease and frontotemporal lobar degeneration subtypes among patients with Corticobasal syndrome","volume":"80","author":"VandeVrede","year":"2023","journal-title":"JAMA Neurol."},{"key":"ref149","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.3389\/fnagi.2022.853050","article-title":"Real-time quaking- induced conversion assays for prion diseases, Synucleinopathies, and Tauopathies","volume":"14","author":"Vascellari","year":"2022","journal-title":"Front. Aging Neurosci."},{"key":"ref150","doi-asserted-by":"publisher","first-page":"484","DOI":"10.3390\/life11060484","article-title":"Impact of TSPO Receptor Polymorphism on [18F]GE-180 Binding in Healthy Brain and Pseudo-Reference Regions of Neurooncological and Neurodegenerative Disorders","volume":"11","author":"Vettermann","year":"2021","journal-title":"Life (Basel)"},{"key":"ref151","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/jon.12932","article-title":"Midbrain area and the hummingbird sign from brain MRI in progressive supranuclear palsy and idiopathic normal pressure hydrocephalus","volume":"32","author":"Virhammar","year":"2022","journal-title":"J. Neuroimaging"},{"key":"ref152","doi-asserted-by":"publisher","first-page":"102197","DOI":"10.1016\/j.arr.2024.102197","article-title":"In vivo imaging of synaptic density in neurodegenerative disorders with positron emission tomography: a systematic review","volume":"94","author":"Visser","year":"2024","journal-title":"Ageing Res. Rev."},{"key":"ref153","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.3233\/JAD-190615","article-title":"Neurofilament light chain in cerebrospinal fluid and blood as a biomarker for neurodegenerative diseases: a systematic review and Meta-analysis","volume":"72","author":"Wang","year":"2019","journal-title":"J. Alzheimer's Dis"},{"key":"ref154","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.parkreldis.2011.05.013","article-title":"Disrupted thalamocortical connectivity in PSP: a resting-state fMRI, DTI, and VBM study","volume":"17","author":"Whitwell","year":"2011","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref155","doi-asserted-by":"publisher","first-page":"102152","DOI":"10.1016\/j.nicl.2019.102152","article-title":"Brain volume and flortaucipir analysis of progressive supranuclear palsy clinical variants","volume":"25","author":"Whitwell","year":"2020","journal-title":"Neuroimage Clin."},{"key":"ref156","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1093\/brain\/awh488","article-title":"Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson\u2019s syndrome and PSP-parkinsonism","volume":"128","author":"Williams","year":"2005","journal-title":"Brain"},{"key":"ref157","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/S1474-4422(09)70042-0","article-title":"Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges","volume":"8","author":"Williams","year":"2009","journal-title":"Lancet Neurol."},{"key":"ref158","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1002\/mds.28991","article-title":"A modified progressive Supranuclear palsy rating scale for virtual assessments","volume":"37","author":"Wills","year":"2022","journal-title":"Mov. Disord."},{"key":"ref159","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1111\/neup.12143","article-title":"Astrocytic inclusions in progressive supranuclear palsy and corticobasal degeneration","volume":"34","author":"Yoshida","year":"2014","journal-title":"Neuropathology"},{"key":"ref160","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1162\/imag_a_00329","article-title":"[18F]PI-2620 tau PET signal across the aging and Alzheimer\u2019s disease clinical spectrum","volume":"2","author":"Young","year":"2024","journal-title":"Imaging Neurosci."},{"key":"ref161","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41586-020-2043-0","article-title":"Novel tau filament fold in corticobasal degeneration","volume":"580","author":"Zhang","year":"2020","journal-title":"Nature"},{"key":"ref162","doi-asserted-by":"publisher","first-page":"13030","DOI":"10.1111\/bpa.13030","article-title":"Distinct subcortical tau burden: the tau pallido-claustral ratio separates progressive supranuclear palsy and corticobasal degeneration","volume":"32","author":"Zhao","year":"2022","journal-title":"Brain Pathol."}],"container-title":["Frontiers in Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2026.1893149\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T05:40:41Z","timestamp":1785130841000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2026.1893149\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":162,"alternative-id":["10.3389\/fnins.2026.1893149"],"URL":"https:\/\/doi.org\/10.3389\/fnins.2026.1893149","relation":{},"ISSN":["1662-453X"],"issn-type":[{"value":"1662-453X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]},"article-number":"1893149"}}